Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a clogged brain drain trigger MS? new MRI study investigates

NCT ID NCT06274671

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study uses special MRI scans to check if the brain's waste-clearing system, called the glymphatic system, is not working properly in people with Clinically Isolated Syndrome (CIS), which is often the first sign of Multiple Sclerosis (MS). Researchers will compare scans from 30 people with CIS to healthy volunteers. The goal is to see if a faulty glymphatic system might contribute to inflammation and brain damage in early MS.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could show that the brain's waste-clearing system plays a role in early MS, paving the way for larger studies on new treatments.
What could go wrong
This is a very small pilot study (30 people) that only looks at scans, not treatments. It may not find clear differences or lead to any direct benefit for patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Group 1: Patients with a diagnosis of Clinically Isolated Syndrome Group 2: Healthy controls

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male or female, aged 18 or over 2. Suitable physically and psychologically to undertake the assessments, as judged by the Investigator 3. Have voluntarily provided informed consent and have signed an ICF indicating that the purpose of the study has been explained and are willing and able to adhere to the study procedures described in the ICF. 4. (For CIS group): A diagnosis of CIS or MS at first presentation 5. Subjects must not have taken corticosteroids or IVIg or plasma-exchange within the 30 days prior to consent 6. Adequate vision and hearing to perform the study procedures 7. Medically healthy with no clinically significant findings on physical examination, laboratory profiles, vital signs at screening (with the exception of the signs of the condition under investigation) 8. Women of child-bearing potential must practice a medically acceptable method of birth control. Acceptable methods include oral contraceptive, contraceptive patch, long-acting injectable contraceptive, or double-barrier method (condom or intrauterine device with spermicide). 9. If on immunomodulatory medication, patients must have started it at least 30 days from screening and should not change their medication dose for the duration of the study. Exclusion Criteria: 1. Have a diagnosis of clinically definite Multiple Sclerosis according to the 2017 McDonald's Criteria (Thompson et al., 2018) 2. Have a CIS limited to the spinal cord (transverse myelitis) 3. Present psychiatric disorders or severe cognitive deficit 4. Past or present history of drug or alcohol abuse 5. Are pregnant or breastfeeding, if females of childbearing potential 6. Have any other medical, neurological, or psychiatric condition or clinically significant laboratory abnormality excluding CIS which, in the opinion of the Investigator, might preclude participation 7. Are taking benzodiazepines on a regular basis or are unable to suspend intake of benzodiazepines 8. Have received any investigational product within a time-period equal to five half-lives of the product, if known, or minimum of 60 days before consent 9. Are unable to lie down for MRI scanning 10. Have any finding on the brain MRI that would compromise subject safety or the scientific integrity of the study 11. Have implants, such as implanted cardiac pacemakers or defibrillators, insulin pumps, cochlear implants, metallic ocular foreign body, implanted neural stimulators, aneurysm clips, or other medical implants that have not been deemed safe for MRI 12. Have a history of claustrophobia 13. Have any other contraindication to MRI scanning 14. Have a relapse occurred after consent but before the MRI scan 15. It is preferable the following laboratory tests are part of the subject's medical history for differential diagnosis of clinically isolated syndrome (CIS): erythrocyte sedimentation rate (ESR), antinuclear antibody (ANA), complement (C3, C4) and anticardiolipin IgG - IgM

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Clinically isolated syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Royal Devon University Healthcare NHS Foundation Trust

    Exeter, United Kingdom

  • University of Exeter

    Exeter, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.